Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.48 |
| ▸ | IKZF2 | Q9UKS7 | 4/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.47 |
| ▸ | WIZ | O95785 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 3/20 | 0.45 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.44 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.44 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31726811 | 1.00 | CRBN (0.52) | CRBNDDB1IKZF2CSNK1A1WIZ | |
| SCHEMBL30984958 | 0.95 | CRBN (0.51) | CRBNDDB1IKZF2CSNK1A1WIZ | |
| SCHEMBL24571664 | 0.94 | CRBN (0.52) | CRBNDDB1IKZF2CSNK1A1WIZ | |
| SCHEMBL31727669 | 0.94 | CRBN (0.52) | CRBNDDB1IKZF2CSNK1A1WIZ | |
| SCHEMBL20234853 | 0.94 | CRBN (0.52) | CRBNDDB1IKZF2CSNK1A1WIZ | |
| SCHEMBL30985233 | 0.94 | CRBN (0.52) | CRBNDDB1IKZF2CSNK1A1WIZ | |
| SCHEMBL31727437 | 0.93 | CRBN (0.52) | CRBNDDB1GSPT1 | |
| SCHEMBL20046704 | 0.93 | CRBN (0.56) | CRBNDDB1IKZF2CSNK1A1WIZ | |
| SCHEMBL31611548 | 0.93 | CRBN (0.56) | CRBNDDB1IKZF2CSNK1A1WIZ | |
| SCHEMBL30720192 | 0.93 | CRBN (0.56) | CRBNDDB1IKZF2CSNK1A1WIZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014260-A1 | MDM2 DEGRADER | NEWAVE PHARMACEUTICAL INC (US) | 2026-01-15 | — | — | US | disclosed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| US-20250002473-A1 | QUINOXALINE DERIVED SULFONAMIDES WITH EGFR DEGRADATION ACTIVITIES AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2025-01-02 | — | — | US | disclosed |
| WO-2024259216-A1 | QUINOXALINE DERIVED SULFONAMIDES WITH EGFR DEGRADATION ACTIVITIES AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| WO-2023230059-A1 | MDM2 DEGRADER | NEWAVE PHARMACEUTICAL INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023139199-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-07-27 | — | — | WO | disclosed |
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-12-15 | — | — | US | disclosed |
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ASTRAZENECA UK LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ASTRAZENECA UK LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
| EP-3947376-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | Astrazeneca AB (SE) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020201080-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ASTRAZENECA AB (SE) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020201080-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ASTRAZENECA AB (SE) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014260-A1 | MDM2 DEGRADER | MDM2, TP53, ADRM1 | CRBN 29/4885DDB1 657/4885IKZF2 3360/4885 |
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ESR1, GPER1, ESRRG | CRBN 576/4885DDB1 1692/4885IKZF2 1887/4885 |
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | CRBN 4/4885DDB1 263/4885IKZF2 50/4885 |
| US-20250002473-A1 | QUINOXALINE DERIVED SULFONAMIDES WITH EGFR DEGRADATION ACTIVITIES AND THEIR USES THEREOF | EGFR, ERBB2, ERBB4 | CRBN 2544/4885DDB1 1305/4885IKZF2 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.